Inhibrx Q2 Loss Widens to $36.7M; Cash at $219.5M After Oxford Draw
INBX has more than doubled off its 52-week low of $22.04.
Summary
Inhibrx's Q2 loss widened to $36.7M, but cash reached $219.5M after drawing from its Oxford facility. PFS data for INBRX-106 is expected in Q3 2026.
Key Events · Earnings and Guidance · INBX
-
Q2 Net Loss Widens
Net loss was $36.7 million ($2.34/share) in Q2 2026, up from $28.7 million ($1.85/share) in Q2 2025, driven by higher R&D and pre-commercialization expenses.
-
Cash Position Strengthened
Cash and equivalents were $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after drawing $100 million from the expanded Oxford loan facility.
-
INBRX-106 PFS Data in Q3 2026
Company plans to announce progression-free survival data from the randomized Phase 2 trial in head and neck squamous cell carcinoma in combination with pembrolizumab during Q3 2026.
-
Ozekibart CRC Expansion
Two additional Phase 1 cohorts in colorectal cancer were initiated in Q2 2026; interim results expected in Q1 2027.
Analysis · INBX · Life Sciences
A wider Q2 net loss of $36.7 million, up from $28.7 million a year ago, reflects higher R&D and pre-commercialization spending. The cash position improved to $219.5 million as of August 6 after drawing $100 million from the expanded Oxford loan facility, providing runway into 2027. Key upcoming catalysts include PFS data from the INBRX-106 Phase 2 trial in Q3 2026 and an FDA meeting in Q4 2026 to discuss ozekibart's registrational path in colorectal cancer.
How filings like this one have moved
In the 30 days to Oct 20, 2026, 29.2% of the 1466 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INBX was trading at $97.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.04 to $155.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.